|
Novocell Obtains U.S. Patent for Drug Screening Human Embryonic Cell Derived-Endoderm Cells.
Business Wire
|
June 3, 2009
|
COPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group.
(Hide copyright information)
Copyright
|
Patent Covers Methods for Identifying Endoderm Differentiation Factors
SAN DIEGO -- Novocell, Inc., a stem cell engineering company, today announced that it has received U.S. Patent No. 7,541,185 with method claims covering the use of endoderm cells derived from human embryonic stem cells (hESCs) for drug discovery. This is the second U.S. patent issued to Novocell related to human endoderm. U.S. Patent No. 7,510,876, issued on March 31, 2009, is directed to an in vitro human endoderm composition.
The patented discovery comes from Novocell's recognized ...
Find more facts and information related to the
article "Novocell Obtains U.S. Patent for Drug Screening ..."
